Ashvattha Therapeutics is pioneering a new class of clinical-stage nanomedicine therapeutics designed to selectively target activated cells in inflamed tissues, thereby redefining precision medicine across various medical fields, including ophthalmology, neurology, and inflammatory diseases. Central to their approach is the use of hydroxyl dendrimer (HD) technology, which enables their nanomedicines to penetrate tissue barriers and deliver treatments with remarkable precision. This targeted delivery system allows for the treatment of conditions such as age-related macular degeneration (AMD) and multiple sclerosis (MS) by ensuring that the therapeutic agents are taken up only by the inflamed tissues, minimizing side effects and enhancing treatment efficacy.

In the realm of ophthalmology, Ashvattha has developed a potent anti-angiogenic nanomedicine that effectively crosses the blood-retinal barrier to target specific cells involved in ocular inflammation. Their innovative imaging agent, 18F-OP-801, is designed to monitor neuroinflammation and assess treatment responses in conditions like MS. Recent preclinical studies have demonstrated the potential of their CSF1R tyrosine kinase inhibitor, CSF1R dendranib, to reduce symptoms in MS models, while the imaging agent has shown promise in detecting neuroinflammation prior to symptom onset. This dual approach of combining targeted therapeutics with advanced imaging techniques positions Ashvattha Therapeutics at the forefront of developing effective treatments for complex inflammatory conditions.

United States

Ashvattha Therapeutics is developing a new class of drugs that identify and treat diseased cells with unprecedented precision. Our proprietary hydroxyl dendrimer (HD) platform, exclusively licensed from Johns Hopkins University, allows for the creation of hydroxyl dendrimer therapeutics (HDTs), which link known small molecule drugs to HDs for selective delivery with sustained effect in diseased tissues. We believe this approach to precision medicine has the potential to change the standard of care across neurology, ophthalmology, hyperinflammatory diseases and neuro-oncology.

Ashvattha Therapeutics

Company Details